Homologous and Heterologous Vaccine Boost Strategies for Humoral and Cellular Immunologic Coverage of the SARS-CoV-2 Omicron Variant
This article has been Reviewed by the following groups
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
- Evaluated articles (ScreenIT)
Abstract
The rapid spread of the highly mutated SARS-CoV-2 Omicron variant has raised substantial concerns about the protective efficacy of currently available vaccines. We assessed Omicron-specific humoral and cellular immune responses in 65 individuals who were vaccinated with two immunizations of BNT162b2 and were boosted after at least 6 months with either Ad26.COV2.S (Johnson & Johnson; N=41) or BNT162b2 (Pfizer; N=24) (Table S1).
Article activity feed
-
SciScore for 10.1101/2021.12.02.21267198: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: The BIDMC institutional review board approved this study (2020P000361).
Consent: All participants provided informed consent.Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources Enzyme-linked immunosorbent assay (ELISA): SARS-CoV-2 spike receptor-binding domain (RBD)-specific binding antibodies in serum were assessed by ELISA as described previously.6,7 96-well plates were coated with 2 μg/mL of SARS-CoV-2 WA1/2020, B.1.617.2 (delta), and B.1.351 (beta) RBD protein in 1× Dulbecco phosphate-buffered saline (DPBS) and incubated at 4 °C overnight. B…SciScore for 10.1101/2021.12.02.21267198: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: The BIDMC institutional review board approved this study (2020P000361).
Consent: All participants provided informed consent.Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources Enzyme-linked immunosorbent assay (ELISA): SARS-CoV-2 spike receptor-binding domain (RBD)-specific binding antibodies in serum were assessed by ELISA as described previously.6,7 96-well plates were coated with 2 μg/mL of SARS-CoV-2 WA1/2020, B.1.617.2 (delta), and B.1.351 (beta) RBD protein in 1× Dulbecco phosphate-buffered saline (DPBS) and incubated at 4 °C overnight. B.1.351suggested: NoneThe plates were again washed 3 times and 50 μL of SULFO-Tagged anti-Human IgG detection antibody diluted to 1x in Diluent 100 was added to each well and incubated shaking at 700 rpm at room temperature for at least 1 h. anti-Human IgGsuggested: (RevMAb Biosciences Cat# 31-1019-MK, RRID:AB_2783627)6 106 peripheral blood mononuclear cells well were re-suspended in 100 µL of R10 media supplemented with CD49d monoclonal antibody (1 µg/mL) and CD28 monoclonal antibody (1 µg/mL). CD49dsuggested: (BD Biosciences Cat# 347690, RRID:AB_647457)CD28suggested: NoneThe next day, the cells were washed twice with DPBS, stained with aqua live/dead dye for 10 mins and then stained with predetermined titers of monoclonal antibodies against CD279 (clone EH12.1, BB700), CD4 (clone L200, BV711), CD27 (clone M-T271, BUV563), CD8 (clone SK1, BUV805), CD45RA (clone 5H9, APC H7) for 30 min. CD279suggested: (BD Biosciences Cat# 566460, RRID:AB_2744348)CD4suggested: NoneCD8suggested: (Abcam Cat# ab34397, RRID:AB_2291359)CD45RAsuggested: NoneCells were washed twice with 1X Perm Wash buffer (BD Perm/WashTM Buffer 10X in the CytoFix/CytoPerm Fixation/ Permeabilization kit diluted with MilliQ water and passed through 0.22µm filter) and stained with intracellularly with monoclonal antibodies against IFN-γ (clone B27; BUV395), and CD3 (clone SP34.2, Alexa 700), for 30 min. IFN-γsuggested: (BD Biosciences Cat# 563563, RRID:AB_2738277)RBD-specific B cell staining: PBMCs were stained with Aqua live/dead dye for 20 min, washed with 2% FBS/DPBS buffer, and cells were suspended in 2% FBS/DPBS buffer with Fc Block (BD) for 10 min, followed by staining with monoclonal antibodies against CD45 (clone HI30, BV786), CD3 (clone UCHT1, APC-R700), CD16 (clone 3G8, BUV496), CD14 (clone M5E2, BV605), CD19 (clone SJ25C, BUV615), CD20 (clone 2H7, PE-Cy5), IgM (clone G20-127, BUV395), IgD (clone IA6-2, PE), CD95 (clone DX2, BV711), CD27 (clone M-T271, BUV563), CD21 (clone B-ly4, PE-CF594), CD38 (clone HB7, BUV805), CD71 (clone M-A712, BV750) and staining with SARS-CoV-2 antigens including biotinylated SARS-CoV-2 (WA1/2020) RBD proteins (Sino Biological), SARS-CoV-2 (WA1/2020) RBD proteins (Sino Biological) labeled with FITC, at 4 °C for 30 min. CD45suggested: (Nanostring Cat# 121300104, RRID:AB_2893077)CD3suggested: (BD Biosciences Cat# 565119, RRID:AB_2744385)CD16suggested: (BD Biosciences Cat# 751323, RRID:AB_2875332)CD14suggested: (BD Biosciences Cat# 564054, RRID:AB_2687593)CD19suggested: (Agilent Cat# TC67401, RRID:AB_579635)CD20suggested: (BD Biosciences Cat# 740204, RRID:AB_2739954)PE-Cy5), IgMsuggested: (Bioss Cat# bs-0336R-PE-Cy5, RRID:AB_10893125)IgDsuggested: (Thermo Fisher Scientific Cat# 24-5093-51, RRID:AB_469565)CD95suggested: (BD Biosciences Cat# 741292, RRID:AB_2870823)CD27suggested: (BD Biosciences Cat# 751679, RRID:AB_2875665)CD21suggested: (BD Biosciences Cat# 748726, RRID:AB_2873130)CD38suggested: (BD Biosciences Cat# 742074, RRID:AB_2871359)CD71suggested: (BD Biosciences Cat# 746857, RRID:AB_2871661)Experimental Models: Cell Lines Sentences Resources Pseudovirus neutralizing antibody assay: The SARS-CoV-2 pseudoviruses expressing a luciferase reporter gene were used to measure pseudovirus neutralizing antibodies as described previously.6,7 In brief, the packaging construct psPAX2 (AIDS Resource and Reagent Program), luciferase reporter plasmid pLenti-CMV Puro-Luc (Addgene) and spike protein expressing pcDNA3.1-SARS-CoV-2 SΔCT were co-transfected into HEK293T cells (ATCC CRL_3216) with lipofectamine 2000 (ThermoFisher Scientific). HEK293Tsuggested: ATCC Cat# CRL-3216, RRID:CVCL_0063)The mixture was incubated at 37 °C for 1 h before adding to HEK293T-hACE2 cells. HEK293T-hACE2suggested: RRID:CVCL_A7UK)Recombinant DNA Sentences Resources Pseudovirus neutralizing antibody assay: The SARS-CoV-2 pseudoviruses expressing a luciferase reporter gene were used to measure pseudovirus neutralizing antibodies as described previously.6,7 In brief, the packaging construct psPAX2 (AIDS Resource and Reagent Program), luciferase reporter plasmid pLenti-CMV Puro-Luc (Addgene) and spike protein expressing pcDNA3.1-SARS-CoV-2 SΔCT were co-transfected into HEK293T cells (ATCC CRL_3216) with lipofectamine 2000 (ThermoFisher Scientific). psPAX2suggested: RRID:Addgene_12260)pLenti-CMV Puro-Lucsuggested: NonepcDNA3.1-SARS-CoV-2suggested: NoneSoftware and Algorithms Sentences Resources Fixed cells were transferred to 96-well round bottom plate and analyzed by BD FACSymphony™ system. BD FACSymphony™suggested: NoneSubsequent analyses were performed using FlowJo software (BD Bioscience, v.9.9.6). FlowJosuggested: (FlowJo, RRID:SCR_008520)Statistical analysis: Descriptive statistics were calculated using GraphPad Prism 8.4.3, (GraphPad Software, San Diego, California). GraphPad Prismsuggested: (GraphPad Prism, RRID:SCR_002798)GraphPadsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title NCT04999111 Recruiting A Study of Ad26.COV2.S Administered as Booster Vaccination i… Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
